Peptide Stack for Weight Loss: Defensible Combinations

A "peptide stack for weight loss" is a combination of two or more peptides used together for body-composition goals. The most evidence-supported combinations are GLP-1 + amylin (CagriSema, Phase 3) and a GLP-1 paired with Tesamorelin specifically for visceral fat. Most informal "weight loss stacks" (AOD-9604, HGH Fragment, MOTS-c additions) do not have evidence to support meaningful additive effect. This article covers the defensible combinations, the speculative ones, and the load-bearing structural advice: resistance training and protein.

For the broader landscape see peptides for weight loss and best peptides for fat loss.

Why most "weight loss stacks" don't work

Informal weight-loss stacks circulating in research-chemical communities often combine:

• A GLP-1 agonist (Semaglutide or Tirzepatide as the workhorse).
• AOD-9604 or HGH Fragment 176-191 as a "fat-burner."
• MOTS-c, AICAR, or 5-Amino-1MQ as a "metabolic enhancer."

The reality:

• The GLP-1 is doing essentially all of the work. The trial data on Semaglutide and Tirzepatide is consistent: 15–21% mean weight loss as monotherapy.
• The AOD-9604 / HGH Fragment addition has no published evidence for additive weight loss in human trials. The compounds didn't work well as monotherapy; adding them to a GLP-1 doesn't fix this.
• MOTS-c, AICAR, and 5-Amino-1MQ have animal data and very limited human data. Adding them on top of a GLP-1 has no clinical evidence to support attributing additional fat loss to the addition.

The takeaway: most stacks are GLP-1 + placebo + placebo. The user-perceived benefit comes from the GLP-1.

The defensible combinations

1. CagriSema (Cagrilintide + Semaglutide)

The most evidence-supported weight-loss stack. Different mechanism (amylin + GLP-1) at the same time. Phase 3 REDEFINE-1 produced ~22% mean weight loss at 68 weeks — meaningfully larger than Semaglutide alone.

This is a true mechanism-complement stack. The amylin axis is biologically separate from the incretin axis; activating both gives the body two parallel satiety signals.

CagriSema is in late-stage Phase 3. Currently not FDA-approved as a fixed combination, but the individual components are available in some channels.

See Cagrilintide explained.

2. GLP-1 + Tesamorelin (for visceral fat specifically)

Tesamorelin is FDA-approved for HIV-associated lipodystrophy — its on-label indication is specifically visceral adipose tissue reduction. Some specialty practices use Tesamorelin alongside a GLP-1 agonist when the goal includes meaningful visceral-fat reduction beyond what GLP-1 monotherapy delivers.

The evidence for the specific combination is limited; the rationale is sound but not trial-proven.

This is a clinically-supervised combination, not a research-chemical stack.

3. GLP-1 + healing peptides (BPC-157, TB-500) for joint discomfort during rapid weight loss

Not a weight-loss stack per se. Rapid weight loss on a GLP-1 can produce joint discomfort and tendon irritation, particularly in users who lose 15+% body weight in 6 months. Some practitioners add BPC-157 or the Wolverine Stack as a supportive intervention.

No evidence for additive weight loss; supportive use only.

4. GLP-1 + resistance training stack ("not technically a peptide stack but it's what matters")

The most important addition to any weight-loss peptide protocol is not another peptide. It is:

• Resistance training 2–4× per week.
• Protein-prioritized diet at 1.6–2.2 g/kg body weight.

20–40% of weight lost on GLP-1 is lean mass without these. With consistent resistance training and protein, that drops to ~10–15%. The composition of weight lost matters far more than the absolute number.

If you can only do one thing to "stack" with your GLP-1, do this.

Combinations to avoid

Two GLP-1s simultaneously

Two GLP-1 agonists at the same time is duplicative, not synergistic. Side-effect risk doubles; weight-loss effect plateaus.

GLP-1 + DNP or other old uncouplers

Cardiac risk is not worth the marginal benefit.

GLP-1 + high-dose stimulants

Additive HR and BP effects. Tachycardia risk in some users.

GLP-1 + diuretics for "rapid weight loss"

Water loss is not fat loss. Will rebound; risks dehydration and electrolyte imbalance.

Multiple research-use weight-loss peptides at the same time

If you stack Semaglutide + AOD-9604 + MOTS-c + 5-Amino-1MQ, you cannot attribute any outcome to any specific compound, and the safety profile is the sum of all four. Cleaner to test one addition at a time, evaluate, then decide.

A defensible cycle plan

For a hypothetical user starting a GLP-1-based weight-loss protocol:

Pre-cycle (weeks -4 to 0):

• Baseline labs: CMP, lipid panel, HbA1c, TSH, body-composition scan (DEXA preferred over scale alone).
• Establish baseline diet and training. Start protein prioritization (1.6–2.2 g/kg).
• Read peptides for weight loss.

Months 1–4 (titration):

• GLP-1 monotherapy, titrating per label or clinician instruction.
• Resistance training 2–4× per week.
• 4-week labs check.

Months 5–12 (maintenance):

• GLP-1 at maintenance dose.
• Reassess at 6 months: weight loss trajectory, body composition, side effects.
• Quarterly labs.

Month 12 evaluation:

• Goal reached: continue at maintenance, plan long-term continuation strategy. Stopping reverses weight loss.
• Goal not reached but trajectory positive: continue at current dose.
• Plateau: discuss CagriSema combination (when available), switch to Tirzepatide if on Semaglutide, or add Tesamorelin for visceral-fat focus — with clinician.

The "stack" doesn't appear in months 1–12. The base GLP-1 plus disciplined training plus protein does most of the work. The actual peptide combinations come in only at month 12+ when monotherapy plateaus or specific goals (visceral fat, joint discomfort) call for them.

Side-effect frame

The stack-specific things to watch:

• CagriSema combination: Slight additive GI side-effect rate over Semaglutide alone; titrate accordingly.
• GLP-1 + Tesamorelin: GH-axis manipulation requires IGF-1 and glucose monitoring on top of standard GLP-1 monitoring.
• GLP-1 + BPC-157 / TB-500: No reported interactions; supportive only.
• GLP-1 + resistance training + protein: No interactions; this combination is what most clinical weight-management programs recommend.

For the full safety frame, see are peptides safe?, peptide side effects, peptide therapy.

Where to go from here

• Peptides for weight loss — pillar with trial data.
• Best peptides for fat loss — ranked roundup.
• Semaglutide vs Tirzepatide, Tirzepatide vs Retatrutide — comparison articles.
• Cagrilintide explained, Retatrutide explained — single-drug explainers.
• Peptide therapy cost — pricing.
• Are peptides safe?, peptide side effects — safety frame.

This is informational, not medical advice. Weight-loss peptide protocols require clinician supervision.